Acquisition by Dunbar George W Jr of 19000 shares of Capricor Therapeutics subject to Rule 16b-3

CAPR Stock  USD 19.04  0.02  0.10%   
Slightly above 55% of Capricor Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Capricor Therapeutics suggests that some traders are interested. Capricor Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Capricor Therapeutics. Many technical investors use Capricor Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Capricor Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Capricor insider trading alert for acquisition of stock option (right to buy) by Dunbar George W Jr, Director, on 28th of May 2024. This event was filed by Capricor Therapeutics with SEC on 2023-01-03. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Capricor Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Capricor Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Capricor Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Capricor Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Capricor Therapeutics Fundamental Analysis

We analyze Capricor Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capricor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capricor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Revenue

Revenue Comparative Analysis

Capricor Therapeutics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Capricor Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Capricor Therapeutics stock to make a market-neutral strategy. Peer analysis of Capricor Therapeutics could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics with similar companies.

Peers

Capricor Therapeutics Related Equities

MCRBSeres Therapeutics   4.55   
0%
42.0%
SCPHScpharmaceuticals   3.89   
0%
36.0%
MISTMilestone Pharmaceuticals   1.08   
0%
10.0%
LUMOLumos Pharma   0.46   
4.0%
0%
IKNAIkena Oncology   1.17   
10.0%
0%
ELYMEliem Therapeutics   1.30   
12.0%
0%
TPSTTempest Therapeutics   2.08   
19.0%
0%
RNXTRenovoRx   7.35   
68.0%
0%
HCWBHCW Biologics   10.71   
100.0%
0%

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.